KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials.

Eur Urol Oncol · 2026-Apr · PMID 39542826

Panel D提取完成待 EXE 对齐验证

Prostate Cancer-Specific Mortality

Fig. 1 – Cumulative incidence and survival plots by prostate subtyping classifier (PSC) subtype for six prostate cancer endpoints. Here, outcomes after treatment by binary PSC subtype categorization (basal subtype [basal immune or basal neuroendocrine] vs luminal subtype [luminal differentiated or luminal proliferating]) are shown for (A) biochemical failure, (B) distant metastases (DMs), (C) metastasis-free survival (MFS), (D) prostate cancer–specific mortality (PCSM), (E) other-cause mortality (OCM), and (F) overall survival (OS). The plots represent the cumulative incidence for endpoints where death serves as a competing risk (BF, DM, PCSM, and OCM) and Kaplan-Meier estimated survival for other endpoints (MFS and OS). BF = biochemical failure; CI = confidence interval; HR = hazard ratio; sHR = subdistributional hazard ratio.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.54
质量通过是
预期曲线2
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证22026-07-23T17:54:35+00:00